vs
Apellis Pharmaceuticals, Inc.（APLS）与SunOpta Inc.（STKL）财务数据对比。点击上方公司名可切换其他公司
SunOpta Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$205.4M vs $199.9M），SunOpta Inc.净利率更高（0.4% vs -29.5%，领先29.9%），SunOpta Inc.同比增速更快（16.6% vs -5.9%），SunOpta Inc.自由现金流更多（$12.1M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs 7.4%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
SunOpta Inc.是一家跨国企业，主营食品与矿产业务，公司1973年于加拿大创立，目前总部位于美国明尼苏达州伊登普雷里，在相关行业领域拥有多年的运营经验与全球化布局。
APLS vs STKL — 直观对比
营收规模更大
STKL
是对方的1.0倍
$199.9M
营收增速更快
STKL
高出22.5%
-5.9%
净利率更高
STKL
高出29.9%
-29.5%
自由现金流更多
STKL
多$26.3M
$-14.3M
两年增速更快
APLS
近两年复合增速
7.4%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $205.4M |
| 净利润 | $-59.0M | $816.0K |
| 毛利率 | — | 12.4% |
| 营业利润率 | -25.6% | 3.3% |
| 净利率 | -29.5% | 0.4% |
| 营收同比 | -5.9% | 16.6% |
| 净利润同比 | -62.2% | 113.1% |
| 每股收益（稀释后） | $-0.40 | $0.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSSTKL
| Q4 25 | $199.9M | — | ||
| Q3 25 | $458.6M | $205.4M | ||
| Q2 25 | $178.5M | $191.5M | ||
| Q1 25 | $166.8M | $201.6M | ||
| Q4 24 | $212.5M | $193.9M | ||
| Q3 24 | $196.8M | $175.9M | ||
| Q2 24 | $199.7M | $169.5M | ||
| Q1 24 | $172.3M | $184.4M |
净利润APLSSTKL
| Q4 25 | $-59.0M | — | ||
| Q3 25 | $215.7M | $816.0K | ||
| Q2 25 | $-42.2M | $4.4M | ||
| Q1 25 | $-92.2M | $4.8M | ||
| Q4 24 | $-36.4M | $-8.7M | ||
| Q3 24 | $-57.4M | $-6.2M | ||
| Q2 24 | $-37.7M | $-5.3M | ||
| Q1 24 | $-66.4M | $2.9M |
毛利率APLSSTKL
| Q4 25 | — | — | ||
| Q3 25 | — | 12.4% | ||
| Q2 25 | — | 14.8% | ||
| Q1 25 | — | 15.0% | ||
| Q4 24 | — | 10.9% | ||
| Q3 24 | — | 13.0% | ||
| Q2 24 | — | 12.5% | ||
| Q1 24 | — | 16.8% |
营业利润率APLSSTKL
| Q4 25 | -25.6% | — | ||
| Q3 25 | 48.7% | 3.3% | ||
| Q2 25 | -18.6% | 5.5% | ||
| Q1 25 | -50.0% | 5.2% | ||
| Q4 24 | -12.3% | 1.4% | ||
| Q3 24 | -24.0% | 0.5% | ||
| Q2 24 | -14.7% | 1.2% | ||
| Q1 24 | -36.0% | 5.5% |
净利率APLSSTKL
| Q4 25 | -29.5% | — | ||
| Q3 25 | 47.0% | 0.4% | ||
| Q2 25 | -23.6% | 2.3% | ||
| Q1 25 | -55.3% | 2.4% | ||
| Q4 24 | -17.1% | -4.5% | ||
| Q3 24 | -29.2% | -3.5% | ||
| Q2 24 | -18.9% | -3.1% | ||
| Q1 24 | -38.5% | 1.6% |
每股收益（稀释后）APLSSTKL
| Q4 25 | $-0.40 | — | ||
| Q3 25 | $1.67 | $0.01 | ||
| Q2 25 | $-0.33 | $0.03 | ||
| Q1 25 | $-0.74 | $0.04 | ||
| Q4 24 | $-0.30 | $-0.08 | ||
| Q3 24 | $-0.46 | $-0.05 | ||
| Q2 24 | $-0.30 | $-0.04 | ||
| Q1 24 | $-0.54 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $2.2M |
| 总债务越低越好 | — | $250.8M |
| 股东权益账面价值 | $370.1M | $162.8M |
| 总资产 | $1.1B | $694.1M |
| 负债/权益比越低杠杆越低 | — | 1.54× |
8季度趋势，按日历期对齐
现金及短期投资APLSSTKL
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | $2.2M | ||
| Q2 25 | $370.0M | $2.2M | ||
| Q1 25 | $358.4M | $2.3M | ||
| Q4 24 | $411.3M | $1.6M | ||
| Q3 24 | $396.9M | $2.9M | ||
| Q2 24 | $360.1M | $3.2M | ||
| Q1 24 | $325.9M | $1.5M |
总债务APLSSTKL
| Q4 25 | — | — | ||
| Q3 25 | — | $250.8M | ||
| Q2 25 | — | $263.3M | ||
| Q1 25 | — | $260.6M | ||
| Q4 24 | — | $265.2M | ||
| Q3 24 | — | $289.9M | ||
| Q2 24 | — | $303.1M | ||
| Q1 24 | $93.1M | $258.8M |
股东权益APLSSTKL
| Q4 25 | $370.1M | — | ||
| Q3 25 | $401.2M | $162.8M | ||
| Q2 25 | $156.3M | $159.8M | ||
| Q1 25 | $164.2M | $154.8M | ||
| Q4 24 | $228.5M | $148.6M | ||
| Q3 24 | $237.1M | $155.0M | ||
| Q2 24 | $264.3M | $158.8M | ||
| Q1 24 | $266.7M | $163.6M |
总资产APLSSTKL
| Q4 25 | $1.1B | — | ||
| Q3 25 | $1.1B | $694.1M | ||
| Q2 25 | $821.4M | $704.9M | ||
| Q1 25 | $807.3M | $690.7M | ||
| Q4 24 | $885.1M | $668.5M | ||
| Q3 24 | $901.9M | $699.3M | ||
| Q2 24 | $904.5M | $704.7M | ||
| Q1 24 | $831.9M | $671.8M |
负债/权益比APLSSTKL
| Q4 25 | — | — | ||
| Q3 25 | — | 1.54× | ||
| Q2 25 | — | 1.65× | ||
| Q1 25 | — | 1.68× | ||
| Q4 24 | — | 1.78× | ||
| Q3 24 | — | 1.87× | ||
| Q2 24 | — | 1.91× | ||
| Q1 24 | 0.35× | 1.58× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $16.3M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $12.1M |
| 自由现金流率自由现金流/营收 | -7.1% | 5.9% |
| 资本支出强度资本支出/营收 | 0.1% | 2.1% |
| 现金转化率经营现金流/净利润 | — | 20.03× |
| 过去12个月自由现金流最近4个季度 | $45.0M | $36.4M |
8季度趋势，按日历期对齐
经营现金流APLSSTKL
| Q4 25 | $-14.2M | — | ||
| Q3 25 | $108.5M | $16.3M | ||
| Q2 25 | $4.4M | $-4.5M | ||
| Q1 25 | $-53.4M | $22.3M | ||
| Q4 24 | $19.4M | $33.1M | ||
| Q3 24 | $34.1M | $17.2M | ||
| Q2 24 | $-8.3M | $-5.6M | ||
| Q1 24 | $-133.0M | $5.3M |
自由现金流APLSSTKL
| Q4 25 | $-14.3M | — | ||
| Q3 25 | $108.3M | $12.1M | ||
| Q2 25 | $4.4M | $-9.2M | ||
| Q1 25 | $-53.4M | $9.5M | ||
| Q4 24 | $19.3M | $24.0M | ||
| Q3 24 | — | $11.7M | ||
| Q2 24 | $-8.4M | $-15.3M | ||
| Q1 24 | $-133.3M | $-2.3M |
自由现金流率APLSSTKL
| Q4 25 | -7.1% | — | ||
| Q3 25 | 23.6% | 5.9% | ||
| Q2 25 | 2.5% | -4.8% | ||
| Q1 25 | -32.0% | 4.7% | ||
| Q4 24 | 9.1% | 12.4% | ||
| Q3 24 | — | 6.6% | ||
| Q2 24 | -4.2% | -9.0% | ||
| Q1 24 | -77.3% | -1.2% |
资本支出强度APLSSTKL
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.0% | 2.1% | ||
| Q2 25 | 0.0% | 2.5% | ||
| Q1 25 | 0.0% | 6.3% | ||
| Q4 24 | 0.0% | 4.7% | ||
| Q3 24 | 0.0% | 3.2% | ||
| Q2 24 | 0.0% | 5.7% | ||
| Q1 24 | 0.2% | 4.1% |
现金转化率APLSSTKL
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | 20.03× | ||
| Q2 25 | — | -1.03× | ||
| Q1 25 | — | 4.63× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.83× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
STKL
| Beverages And Broths | $161.4M | 79% |
| Fruit Snacks | $40.9M | 20% |
| Ingredients | $3.1M | 2% |
